NSIS B — Novozymes A/S Balance Sheet
0.000.00%
- DKK192.47bn
- DKK203.76bn
- €3.83bn
- 75
- 11
- 73
- 52
Annual balance sheet for Novozymes A/S, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | fx Final | fx Final | fx Final | fx Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 175 | 140 | 151 | 155 | 284 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 434 | 510 | 581 | 583 | 863 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 929 | 1,052 | 1,243 | 1,269 | 1,879 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1,292 | 1,370 | 1,624 | 1,653 | 2,968 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 2,756 | 3,331 | 3,764 | 3,809 | 15,196 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 559 | 763 | 937 | 974 | 1,088 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 1,247 | 1,740 | 1,903 | 1,934 | 4,020 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 1,510 | 1,591 | 1,861 | 1,875 | 11,176 |
Total Liabilities & Shareholders' Equity | 2,756 | 3,331 | 3,764 | 3,809 | 15,196 |
Total Common Shares Outstanding |